Dec 1, 2022
NCT05271630: Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Transplant
NCT05271630: Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant Multiple Myeloma Outcomes Based...
132
Dec 1, 2022
NCT05231629: Phase 2: Sequential Therapy in Multiple Myeloma Guided by MRD Assessments (MASTER-2)
MASTER-2 NCT05231629: Phase 2: Sequential Therapy in Multiple Myeloma Guided by MRD Assessments (MASTER-2) NCT05231629: Phase 2:...
625
Dec 30, 2021
NCT04934475: Phase 3 - IFM 2020-02 Minimal Residual Disease Adapted Strategy (MIDAS) KRD-Isatuximab
IFM 2020-02 MInimal Residual Disease Adapted Strategy (MIDAS) Isa-KRd NCT04934475: Phase 3 - IFM 2020-02 -MInimal Residual Disease...
1,985
Dec 3, 2021
NCT05083169: Phase 3 - Tec-Dara Vs DPd Vs DVd in Relapsed or Refractory Myeloma - MajesTEC-3
MajesTEC-3 A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and...
1,056
Aug 6, 2021
NCT04816526: Phase 2 - Descartes-08 anti-BCMA-CAR-mRNA-transf. auto CD8+ T cells Consolidation MRD+
NCT04816526: Phase 2 - Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After...
227
Jun 24, 2021
NCT04939844: Phase 2: REST - Replacing Steroids in the Transplant Ineligble (REST)
REST NCT04939844: Phase 2: REST - Replacing Steroids in the Transplant Ineligble (REST) Newly diagnosed multiple myeloma patients...
112
Dec 10, 2020
The clonoSEQ® Watch Registry
The clonoSEQ® Watch Registry Real World Observational Study Using clonoSEQ® Next Generation Sequencing in Hematologic Malignancies: The...
253
Dec 6, 2020
NCT04484623: Phase 3 - Belantamab Mafodotin & Pom/Dex (Pd) Vs Bortezomib & Pd in Ref. MM (DREAMM 8)
DREAMM 8 Relapsed & Refractory Myeloma Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in...
805
Dec 2, 2020
NCT04436029: Phase 2: Descartes-11 Consolidation Treatment Patients With High-Risk Multiple Myeloma
NCT04436029: Phase 2: Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After...
129
Dec 1, 2020
NCT04268498: Phase2 - Daratumumab, Carfilzomib, Lenalidomide, Dex NDMM Multiple Myeloma (ADVANCE)
The ADVANCE trial Dara-KRd KRd VRd NCT04268498: A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With...
1,115
Dec 1, 2020
NCT04236011: Phase 1: BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Myeloma
NCT04236011: Phase 1: BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Multiple Myeloma BCMA and CD19 Targeted Fast...
320
Dec 1, 2020
NCT04221178: Stopping Maintenance Therapy in People With Multiple Myeloma in MRD-Negative Remission
NCT04221178: Stopping Maintenance Therapy in People With Multiple Myeloma in MRD-Negative Remission NCT04221178: Stopping Maintenance...
88
Dec 1, 2020
NCT04513639: Phase 2/3: The Relapse From MRD Negativity as Indication for Treatment (REMNANT) Study
NCT04513639: Phase 2/3: The Relapse From MRD Negativity as Indication for Treatment (REMNANT) Study Dara-Kd The Relapse From MRD...
496
Dec 19, 2019
NCT04133636: Phase 2 - Study of JNJ-68284528, CAR-T Therapy Directed Against BCMA in MM -CARTITUDE-2
CARTITUDE-2 Ciltacabtagene Autoleuce A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell...
776
Dec 18, 2019
NCT03901963: Phase 3 - Dara + Len vs Len as Maint. in New Myeloma +MRD after frontline ASCT (AURIGA)
AURIGA Study A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly...
1,084
Dec 14, 2019
NCT04071457: Phase 3: S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maint. NDMM DRAMMATIC
DRAMMATIC SWOG S1803 NCT04071457: Phase 3: S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct...
1,184
Dec 13, 2019
NCT04009109: Phase 2 - Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in TIE NDMM
NCT04009109: Phase 2 - Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM...
202
Dec 13, 2019
NCT04108624: Study to Assess for Measurable Residual Disease (MRD) in Multiple Myeloma Patients
Study to Assess for Measurable Residual Disease (MRD) in Multiple Myeloma Patients Study to Assess for Measurable Residual Disease (MRD)...
318
Dec 13, 2019
NCT03896737: Phase 2: EMN 18 - Dara-VCd VS VTd Then Maintenance With Ixazomib (IXA) or IXA-Dara
EMN 18 Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib...
223